Qlife Holding AB (FRA:4HG0) Research & Development: €0.00 Mil (TTM As of Mar. 2026)


FRA:4HG0 Qlife Holding AB FRA:4HG0
25 GF Score
Price €0.16
GF Value €0.06
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Qlife Holding AB Research & Development?

Qlife Holding AB FRA:4HG0 +4.03% 25 Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:4HG0 with a GF Score™ of 25/100 and a GF Value™ of €0.06 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Qlife Holding AB's Research & Development for the three months ended in Mar. 2026 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Qlife Holding AB  (FRA:4HG0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Qlife Holding AB Research & Development Related Terms

Qlife Holding AB Research & Development Historical Data

* Premium members only.

The historical data trend for Qlife Holding AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qlife Holding AB Research & Development Chart

Qlife Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial -2.49 -4.25 0.00 0.00 0.00

Qlife Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:4HG0
25GF Score
Qlife Holding AB FRA:4HG0
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qlife Holding AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Qlife Holding AB (FRA:4HG0) has a Research & Development of €0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Qlife Holding AB and its competitors.
Is Qlife Holding AB's Research & Development too high?
Qlife Holding AB's current Research & Development is €0.00 Mil. Overall, Qlife Holding AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's Research & Development compare to ABT and SYK?
Qlife Holding AB's Research & Development of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Qlife Holding AB and its competitors. Qlife Holding AB's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (FRA:4HG0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.16 — trading 167% above its estimated fair value. The current Research & Development is €0.00 Mil. Qlife Holding AB's overall GF Score™ is 25/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Qlife Holding AB (FRA:4HG0), the current Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qlife Holding AB (FRA:4HG0) Overvalued in 2026?

Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued. The current stock price of €0.16 is trading 167% above its estimated GF Value™ of €0.06. GuruFocus considers Qlife Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:4HG0:

  • Research & Development: €0.00 Mil
  • GF Value™: €0.06 vs. price of €0.16 (167% above fair value)
  • GF Score™: 25/100 with 9 warning signs

No single metric tells the full story. See the FRA:4HG0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Qlife Holding AB Business Description

Other Exchanges QLIFE:Sweden
Address Nellikevagen 22, Goteborg, SWE, SE-412 63
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
25GF Score

Get the complete analysis for FRA:4HG0

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.06
GF Value